Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants With Hereditary Angioedema (HAE)

NCT06842823 is registered in ClinicalTrials.gov with Astria Therapeutics, Inc. as lead sponsor.

NCT NCT06842823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06842823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants With Hereditary Angioedema (HAE)
Lead sponsor
Astria Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 20, 2025
Completion date
June 30, 2027
Enrollment
157 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)